Abstract
Similar to findings in the nephrotic syndrome in humans, rats with the doxorubicin-induced nephrotic syndrome (which resembles minimal change disease) have reduced serum levels of insulin-like growth factor-I (IGF-I). This is mainly caused by glomerular ultrafiltration of IGF-I-containing binding protein complexes, primarily of a molecular weight of approximately 50 kilodaltons, and urinary losses of the peptide. Despite urinary excretion of IGF-binding protein (IGFBP)-2, serum levels are increased more than twofold in the nephrotic syndrome compared with controls, because of increased synthesis of this binding protein by the liver. In contrast, the liver synthesis of IGFBP-3, the predominant binding protein in normal serum, is unchanged in the nephrotic syndrome. However, binding and serum levels of IGFBP-3 are reduced in nephrotic rat serum, apparently due to proteolytic degradation of IGFBP-3. The glomerular ultrafiltration of IGF-I, which leads to biologically significant IGF-I concentrations of about 1.35 nM in proximal tubule fluid, may have metabolic consequences, such as increased tubular phosphate absorption. Hypothetically, tubule fluid IGF-I may also contribute to progressive tubulointerstitial fibrosis which is sometimes present in protractive nephrotic glomerulopathies. The profound changes in the IGF-I/IGFBP system in the nephrotic syndrome may also contribute to systemic metabolic abnormalities and growth failure.
Similar content being viewed by others
References
Frystyk J, Skjaerbaek C, Dinesen B, Orskov H (1994) Free insulin-like growth factor (IGF-I and IGF-II) in human serum. FEBS Lett 348:185–191
Hintz R, Liu F (1977) Demonstration of specific plasma binding sites for somatomedin. J Clin Endocrinol Metab 45:988–995
Baxter R, Martin T (1989) Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA 86:6898–6902
Holly J (1993) Insulin-like growth factor binding proteins in diabetic and non-diabetic states. In: Flyvbjerg AS, Orskov H, Alberti K (eds) Growth hormone and insulin-like growth factor I in human and experimental diabetes. Wiley, Chichester, UK, pp 47–76
Hodgkinson S, Davis S, Burleigh B, Henderson H, Gluckman P (1987) Metabolic clearance rate of insulin-like growth factor-I in fed and starved sheep. J Endocrinol 115:233–240
Blat C, Villaudy J, Binoux M (1994) In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 93: 2286–2290
Hirschberg R, Kopple J, Blantz R, Tucker B (1991) Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat. J Clin Invest 87:1200–1206
Hirschberg R, Kopple J (1995) IGF-I and renal function. Diabetes Rev 3:177–195
D'Ercole A, Underwood L (1987) Estimation of tissue concentrations of somatomedin C/insulin-like growth factor I. Methods Enzymol 146:227–233
Roberts C, Lasky S, Lowe W, Seaman W, LeRoith D (1987) Molecular cloning of rat insulin-like growth factor I complementary deoxyribonucleic acids: differential messenger ribonucleic acid processing and regulation by growth hormone in extrahepatic tissues. Mol Endocrinol 1:243–248
Chin E, Zhou J, Bondy C (1992) Anatomical relationships in the pattern of insulin-like growth factor (IGF)-I, IGF binding protein-1 and IGF-1 receptor gene expression in the rat kidney. Endocrinology 130:3237–3245
Yokoya S, Suwa S, Maesaka H, Tanaka T (1988) Immunoreactive somatomedin C/insulin-like growth factor I in urine from normal subjects, pituitary dwarfs, and acromegalics. Pediatr Res 23: 151–154
Hizuka N, Takano K, Tanaka I, Asakawa K, Miyakawa M, Horikawa R, Shizume K (1987) Demonstration of insulin-like growth factor I in human urine. J Clin Endocrinol Metab 64:1309–1312
Quattrin T, Albini C, Cara J, Vandlen R, Mills B, MacGillivray M (1987) Quantitation of urinary somatomedin-C and growth hormone in preterm and fullterm infants and normal children. J Clin Endocrinol Metab 66:792–797
Gargosky S, Hasegawa T, Tapaniainen P, MacGillivray M, Hasegawa Y, Rosenfeld R (1993) Urinary insulin-like growth factors (IGF) and IGF-binding proteins in normal subjects, growth hormone deficiency, and renal disease. J Clin Endocrinol Metab 76: 1631–1637
Zumkeller W, Hall K (1990) Immunoreactive insulin-like growth factor II in urine. Acta Endocrinol (Copenh) 123:499–503
Hirschberg R (1993) IGF-I is ultrafiltered into the urinary space and may exert biological effects in proximal tubules in the nephrotic syndrome. J Am Soc Nephrol 4:771
Hirschberg R, Kaysen G (1995) Insulin-like growth factor I and its binding proteins in the experimental nephrotic syndrome. Endocrinology 136:1565–1571
Thabet M, Challa AS, Chan W, Liu F, Hintz R, Chan J (1994) Insulin-like growth factor and growth hormone in the nephrotic syndrome. Am J Physiol 266:E102-E106
Garin E, Grant M, Janet H, Silverstein M (1989) Insulinlike growth factors in patients with active nephrotic syndrome. Am J Dis Child 143:865–867
Quigley R, Baum M (1991) Effects of growth hormone and insulin-like growth factor I on renal convoluted tubule transport. J Clin Invest 88:368–374
Hirschberg R, Ding H, Wanner C (1995) Effects of insulin-like growth factor I on phosphate transport in cultured proximal tubule cells. J Lab Clin Med 125:428–434
Feld S, Hirschberg R, Artishevsky A, Nast C, Adler S (1995) Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int 48:45–51
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feld, S.M., Hirschberg, R. Insulin-like growth factor-I and insulin-like growth factor-binding proteins in the nephrotic syndrome. Pediatr Nephrol 10, 355–358 (1996). https://doi.org/10.1007/BF00866783
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00866783